Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 9/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.38 |
| ▸ | BTK | Q06187 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655687 | 0.87 | ATR (0.54) | ATRPIK3CDBTK | |
| SCHEMBL16655403 | 0.78 | ATR (0.56) | ATRPIK3CDBTK | |
| SCHEMBL23917257 | 0.75 | JAK2 (0.47) | BTK | |
| SCHEMBL23917547 | 0.71 | PIK3CD (0.45) | ATRPIK3CDBTKPIK3CAPIK3CB | |
| SCHEMBL23917242 | 0.70 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL16655634 | 0.62 | ATR (0.66) | ATRPIK3CDBTKLCKRET | |
| SCHEMBL16655488 | 0.62 | ATR (0.59) | ATRPIK3CDBTKPIK3CAPIK3CB | |
| SCHEMBL16655550 | 0.62 | ATR (0.56) | ATRPIK3CDBTKPIK3CAPIK3CB | |
| SCHEMBL16655576 | 0.61 | JAK2 (0.55) | ATRPIK3CDBTK | |
| SCHEMBL23917267 | 0.60 | PIK3CD (0.51) | ATRPIK3CDBTKPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | ATR 680/4885PIK3CD 2/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.